The role of CA 125 as tumor marker: Biochemical and clinical aspects

Advances in Experimental Medicine and Biology

Volumn 867, Issue , 2015, Pages 229-244

  Bottoni, Patrizia ^a   Scatena, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

CA 125; CA 125 clinical use; CA 125 measurement; CA 125 nadir; HE4; Membrane associated mucins; MUC16; MUC16 biochemical structure; Mucins biological functions; OVA1 algorithm; Ovarian cancer; Ovarian cancer monitoring; ROMA algorithm; Secreted mucins

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; MUCIN; MUCIN16; TUMOR MARKER; UNCLASSIFIED DRUG; PROTEIN; WFDC2 PROTEIN, HUMAN;

ALGORITHM; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEASUREMENT; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN SECRETION; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; BLOOD; EARLY DIAGNOSIS; FEMALE; OVARIAN NEOPLASMS;

ALGORITHMS; CA-125 ANTIGEN; EARLY DETECTION OF CANCER; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 84946779960     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-94-017-7215-0_14     Document Type: Chapter

References (90)

1. Senapati S, Das S, Batra SK (2010) Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci 35:236–245
2. Rose MC, Voynow JA (2006) Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 86:245–278
3. Gendler SJ, Burchell JM, Duhig T et al (1987) Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. Proc Natl Acad Sci U S A 84:6060–6064
4. Gupta R, Jentoft N (1989) Subunit structure of porcine submaxillary mucin. Biochemistry 28:6114–6121
5. Timpte CS, Eckhardt AE, Abernethy JL, Hill RL (1988) Porcine submaxillary gland apomucin contains tandemly repeated, identical sequences of 81 residues. J Biol Chem 263:1081–1088
6. Lang T, Hansson GC, Samuelsson T (2007) Gelforming mucins appeared early in metazoan evolution. Proc Natl Acad Sci U S A 104:16209–16214
7. Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4:45–60
8. Chen Y, Zhao YH, Kalaslavadi TB et al (2004) Genome-wide search and identifi cation of a novel gelforming mucin MUC19/Muc19 in glandular tissues. Am J Respir Cell Mol Biol 30:155–165
9. Corfi eld AP (2015) Mucins: a biologically relevant glycan barrier in mucosal protection. Biochim Biophys Acta 1850:236–252
10. Kufe DW (2009) Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 9:874–885
11. Carraway KL, Ramsauer VP, Haq B, Carothers Carraway CA (2003) Cell signaling through membrane mucins. Bioessays 25:66–71
12. Jepson S, Komatsu M, Haq B et al (2002) Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specifi c phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways. Oncogene 21:7524–7532
13. Levitin F, Stern O, Weiss M et al (2005) The MUC1 SEA module is a self-cleaving domain. J Biol Chem 280:33374–33386
14. Gendler SJ, Spicer AP (1995) Epithelial mucin genes. Annu Rev Physiol 57:607–634
15. Singh AP, Moniaux N, Chauhan SC et al (2004) Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 64:622–630
16. Chan AK, Lockhart DC, von Bernstorff W (1999) Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation. Int J Cancer 82:721–726
17. Argueso P, Guzman-Aranguez A, Mantelli F et al (2009) Association of cell surface mucins with galectin- 3 contributes to the ocular surface epithelial barrier. J Biol Chem 284:23037–23045
18. Seelenmeyer C, Wegehingel S, Lechner J, Nickel W (2003) The cancer antigen CA125 represents a novel counter receptor for galectin-1. J Cell Sci 116:1305–1318
19. Patankar MS, Jing Y, Morrison JC et al (2005) Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol 99:704–713
20. Belisle JA, Gubbels JA, Raphael CA et al (2007) Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 122:418–429
21. Gubbels JA, Belisle J, Onda M et al (2006) Mesothelin-MUC16 binding is a high affi nity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 5:50
22. Rump A, Morikawa Y, Tanaka M (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279:9190–9198
23. Bergan L, Gross JA, Nevin B et al (2007) Development and in vitro validation of antimesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. Cancer Lett 255:263–274
24. Kaneko O, Gong L, Zhang J et al (2009) A binding domain on mesothelin for CA125/MUC16. J Biol Chem 284:3739–3749
25. Bast RC Jr, Feeney M, Lazarus H et al (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337
26. Bast RC Jr., Klug TL, St. John E et al (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883
27. Bast RC Jr, Xu FJ, Yu YH et al (1998) CA 125: the past and the future. Int J Biol Markers 13:179–187
28. Sturgeon CM, Duffy MJ, Stenman UH et al (2008) National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54:e11–e79
29. Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P (1998) Comparison of seven immunoassays for the quantifi cation of CA 125 antigen in serum. Clin Chem 44:1417–1422
30. Shih Ie M, Sokoll L, Chan DW (2002) Ovarian cancer. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK (eds) Tumor markers: physiology, pathobiology, technology and clinical applications. AACC Press, Washington, DC, pp 239–252
31. Masahashi T, Matsuzawa K, Ohsawa M et al (1988) Serum CA 125 levels in patients with endometriosis: changes of CA 125 levels during menstruation. Obstet Gynecol 72:328
32. Bergmann JF, Beaugrand M, Labadie H et al (1986) CA 125 (ovarian tumour-associated antigen) in ascitic liver diseases. Clin Chim Acta 155:163
33. Molina R, Ballesta AM, Casals E et al (1984) Value of CA 125 antigen as tumor marker: preliminary results. In: Peeters H (ed) Protides of the biological fl uids. Proceedings of the 32nd Colloquium, Brussels, p 613
34. Ruibal A, Encabo G, Miralles EM et al (1984) CA 125 seric levels in non ovarian pathologies. In: Peeters H (ed) Protides of the biological fl uids. Proceedings of the 32nd Colloquium, Brussels, p 605
35. Giudice LC, Jacobs A, Pineda J et al (1986) Serum levels of CA 125 in patients with endometriosis: a preliminary report. Fertil Steril 45(6):876
36. Malkasian GD Jr., Podratz KC, Stanhope CR et al (1986) CA 125 in gynecologic practice. Am J Obstet Gynecol 155:515
37. Haga Y, Sakamoto K, Egami H et al (1986) Evaluation of serum CA 125 values in healthy individuals and pregnant women. Am J Med Sci 292:25
38. Halila H, Stenman UH, Seppala M (1986) Ovarian cancer antigen CA 125. Levels in pelvic infl ammatory disease and pregnancy. Cancer 57:1327
39. Pittaway DE, Fayez JA, Douglas JW (1987) Serum CA 125 in the evaluation of benign adnexal cysts. Am J Obstet Gynecol 157:1426
40. Niloff JM, Knapp RC, Schaetzl E et al (1984) CA 125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 64:703
41. Haga Y, Sakamoto K, Egami H et al (1986) Clinical signifi cance of serum CA 125 values in patients with cancers of the digestive system. Am J Med Sci 292:30
42. Duk JM, Aalders JG, Fleuren GJ et al (1986) CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 155:1097
43. Bertholf RL, Johannsen L, Guy B (2002) False elevation of serum CA-125 level caused by human antimouse antibodies. Ann Clin Lab Sci 32:414–418
44. Boerman OC, Segers MF, Poels LG et al (1990) Heterophilic antibodies in human sera causing falsely increased results in the CA 125 immunofl uorometric assay. Clin Chem 36:888–891
45. Young RH, Clement PB, Scully RE, Sternberg SS (1999) The ovary: diagnostic surgical pathology, vol Lippin cott Williams & Wilkins, Philadelphia, pp 2307–2394
46. Scully RE (ed) (1999) Histological typing of ovarian tumours, 2nd edn, Sobin LH and pathologists in 5 countries, collaborators. Springer, New York, p 136
47. Seidman JD, Horkayne-Szakaly I, Haiba M et al (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23:41–44
48. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403
49. Fleisher M, Dnistrian A, Sturgeon C, Lamerz R, Witliff J (2002) Practice guidelines and recommendations for use of tumor markers in the clinic. Tumor markers: physiology, pathobiology, technology and clinical applications. AACC Press, Washington, DC, pp 33–63
50. NCCN [National Comprehensive Cancer Network] Clinical Practice Guidelines in Oncology (2008) Ovarian cancer. Version http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf. Accessed Nov 2008
51. Vasey PA, Herrstedt J, Jelic S (2005) ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma. Ann Oncol 16(Suppl 1):i13–i15
52. Skates SJ, Xu FJ, Yu YH et al (1995) Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76:2004–2010
53. Bast RC Jr, Brewer M, Zou C et al (2007) Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 174:91–100
54. Bast RC Jr, Urban N, Shridhar V et al (2002) Early detection of ovarian cancer: promise and reality. Cancer Treat Res 107:61–97
55. Zhang Z, Bast RC Jr, Yu Y et al (2004) Three biomarkers identifi ed from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64:5882–5890
56. Kobayashi H, Yamada Y, Sado T et al (2008) A randomized study of screening for ovarian cancer: a mul- ticenter study in Japan. Int J Gynecol Cancer 18:414–420
57. Buys SS, Partridge E, Black A et al (2011) Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305:2295–2303
58. Menon U, Gentry-Maharaj A, Hallett R et al (2009) Sensitivity and specifi city of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10:327–340
59. Menon U, Griffi n M, Gentry-Maharaj A (2014) Ovarian cancer screening-current status, future directions. Gynecol Oncol 132:490–495
60. Duffy MJ, Bonfrer JM, Kulpa J et al (2005) CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use. Int J Gynecol Cancer 15:679–691
61. Gronlund B, Hogdall C, Hilden J et al (2004) Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 22:4051–4058
62. Su Z, Graybill WS, Zhu Y (2013) Detection and monitoring of ovarian cancer. Clin Chim Acta 415:341–345
63. Rustin GJ, Vergote I, Eisenhauer E et al (2011) Defi nitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21:419–423
64. Gadducci A, Fuso L, Cosio S et al (2009) Are surveillance procedures of clinical benefi t for patients treated for ovarian cancer?: a retrospective Italian multicentric study. Int J Gynecol Cancer 19:367–374
65. Nadal RM, Ojeda BM, Artigas V et al (2006) Stratifi cation of the normal range of CA-125 after chemotherapy as a predictive factor in carcinoma of the ovary. J Clin Oncol 24:270 s (suppl; abstr 5059)
66. Tanabe H, Katsumata N, Matsumoto K et al (2006) CA-125 nadir as a prognostic factor in advanced ovarian carcinoma: a retrospective study of 84 patients achieving clinical CR. J Clin Oncol 24:270 s (suppl; abstr 5060)
67. Markman M, Liu PY, Rothenberg ML et al (2006) Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 24:1454–1458
68. Liu PY, Alberts DS, Monk BJ et al (2007) An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 25:3615–3620
69. Prat A, Parera M, Peralta S et al (2008) Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol 19:327–331
70. Clauss A, Lilja H, Lundwall A (2002) A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J 368:233–242
71. Hellstrom I, Raycraft J, Hayden-Ledbetter M et al (2003) The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63:3695–3700
72. Li J, Dowdy S, Tipton T et al (2009) HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 9:555–566
73. Bingle L, Singleton V, Bingle CD (2002) The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 21:2768–2773
74. Ferraro S, Schiumarini D, Panteghini M (2015) Human epididymis protein 4: factors of variation. Clin Chim Acta 438:171–177
75. Moore RG, Miller MC, Eklund EE (2012) Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 206(349):e1–e7
76. Huhtinen K, Suvitie P, Hiissa J et al (2009) Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 100:1315–1319
77. Anastasi E, Marchei GG, Viggiani V et al (2010) HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 31:113–119
78. Hynninen J, Auranen A, Dean K et al (2011) Serum HE4 profi le during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer 21:1573–1578
79. Manganaro L, Michienzi S, Vinci V et al (2013) Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. Oncol Rep 30:2481–2487
80. ROMA™ (HE4 EIA + ARCHITECT CA 125 IITM) Prescribing Information (2011) Fujirebio Diagnostics, Inc.
81. Kalapotharakos G, Asciutto C, Henic E et al (2012) High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res 5:20
82. Sandri MT, Bottari F, Franchi D et al (2013) Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol 128:233–238
83. Wang J, Gao J, Yao H et al (2014) Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. Tumour Biol 35:6127–6138
84. Chudecka-Głaz AM (2015) ROMA, an algorithm for ovarian cancer. Clin Chim Acta 440:143–151
85. Zhang Z, Chan DW (2010) The road from discovery to clinical diagnostics: lessons learned from the fi rst FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 19:2995–2999
86. Fung ET (2010) A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 56:327–329
87. Ueland FR, Desimone CP, Seamon LG et al (2011) Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 117:1289–1297
88. Bristow RE, Smith A, Zhang Z et al (2013) Ovarian malignancy risk stratifi cation of the adnexal mass using a multivariate index assay. Gynecol Oncol 128:252–259
89. Grenache DG, Heichman KA, Werner TL, Vucetic Z (2015) Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass. Clin Chim Acta 438:358–363
90. Lokshin AE (2012) The quest for ovarian cancer screening biomarkers: are we on the right road? Int J Gynecol Cancer 22(Suppl 1):S35–S40